Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, Yerin | - |
dc.contributor.author | Yu, Sora | - |
dc.contributor.author | Liu, Jing-Jing | - |
dc.contributor.author | Yun, Eun Ju | - |
dc.contributor.author | Lee, Jae Won | - |
dc.contributor.author | Jin, Yong-Su | - |
dc.contributor.author | Kim, Kyoung Heon | - |
dc.date.accessioned | 2022-02-25T08:40:22Z | - |
dc.date.available | 2022-02-25T08:40:22Z | - |
dc.date.created | 2022-02-07 | - |
dc.date.issued | 2021-08-18 | - |
dc.identifier.issn | 1475-2859 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136839 | - |
dc.description.abstract | Background: Saccharomyces cerevisiae var. boulardii is a representative probiotic yeast that has been widely used in the food and pharmaceutical industries. However, S. boulardii has not been studied as a microbial cell factory for producing useful substances. Agarose, a major component of red macroalgae, can be depolymerized into neoagarooligosaccharides (NAOSs) by an endo-type beta-agarase. NAOSs, including neoagarotetraose (NeoDP4), are known to be health-benefiting substances owing to their prebiotic effect. Thus, NAOS production in the gut is required. In this study, the probiotic yeast S. boulardii was engineered to produce NAOSs by expressing an endo-type beta-agarase, BpGH16A, derived from a human gut bacterium Bacteroides plebeius. Results: In total, four different signal peptides were compared in S. boulardii for protein (BpGH16A) secretion for the first time. The SED1 signal peptide derived from Saccharomyces cerevisiae was selected as optimal for extracellular production of NeoDP4 from agarose. Expression of BpGH16A was performed in two ways using the plasmid vector system and the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 system. The production of NeoDP4 by engineered S. boulardii was verified and quantified. NeoDP4 was produced by S. boulardii engineered using the plasmid vector system and CRISPR-Cas9 at 1.86 and 0.80 g/L in a 72-h fermentation, respectively. Conclusions: This is the first report on NAOS production using the probiotic yeast S. boulardii. Our results suggest that S. boulardii can be considered a microbial cell factory to produce health-beneficial substances in the human gut. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.subject | GUT MICROBIOTA | - |
dc.subject | IN-VITRO | - |
dc.subject | AGAR | - |
dc.subject | OLIGOSACCHARIDES | - |
dc.subject | TRANSFORMATION | - |
dc.subject | PURIFICATION | - |
dc.subject | HYDROLYSIS | - |
dc.subject | EXPRESSION | - |
dc.subject | PROTEINS | - |
dc.subject | BACTERIA | - |
dc.title | Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kyoung Heon | - |
dc.identifier.doi | 10.1186/s12934-021-01644-w | - |
dc.identifier.scopusid | 2-s2.0-85112784627 | - |
dc.identifier.wosid | 000686642900002 | - |
dc.identifier.bibliographicCitation | MICROBIAL CELL FACTORIES, v.20, no.1 | - |
dc.relation.isPartOf | MICROBIAL CELL FACTORIES | - |
dc.citation.title | MICROBIAL CELL FACTORIES | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.subject.keywordPlus | AGAR | - |
dc.subject.keywordPlus | BACTERIA | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | GUT MICROBIOTA | - |
dc.subject.keywordPlus | HYDROLYSIS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | OLIGOSACCHARIDES | - |
dc.subject.keywordPlus | PROTEINS | - |
dc.subject.keywordPlus | PURIFICATION | - |
dc.subject.keywordPlus | TRANSFORMATION | - |
dc.subject.keywordAuthor | BpGH16A | - |
dc.subject.keywordAuthor | CRISPR-Cas9 | - |
dc.subject.keywordAuthor | Neoagarooligosaccharides | - |
dc.subject.keywordAuthor | Prebiotics | - |
dc.subject.keywordAuthor | Probiotics | - |
dc.subject.keywordAuthor | Saccharomyces boulardii | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.